Senescence — the second escape route

Senescence means a cell is alive, active, and not dividing.

That sounds helpful at first.

In cancer, it is not always the end of the story.

McGrath et al. (2024) argue that reversible senescence may protect surviving ER-positive cells long enough for later escape.

What senescence looks like

Senescent cells usually become larger and flatter.

They stop cycling.

They also change what they secrete.

That secretory program is called SASP.

SASP stands for senescence-associated secretory phenotype.

It includes inflammatory signals such as IL-6, IL-8, and matrix-remodelling factors.

Why SASP matters

A sleeping cancer cell can still change its environment.

That is the real concern.

SASP can:

• stimulate nearby cells

• support angiogenesis

• promote inflammation

• weaken immune control

So even if a senescent cell is not dividing, it may still help the wider disease.

The key shift in thinking

Senescence used to be treated as permanent.

The authors push against that older view.

In breast-cancer models, some senescent cells can re-enter the cell cycle after treatment is removed.

That makes senescence less like a dead end and more like a holding bay.

How antiestrogen therapy fits in

Tamoxifen can induce senescence through a ROS → p53 → p21 route.

McGrath et al. (2024) also highlight YPEL3 as an important mediator.

Non-steroidal aromatase inhibitors such as letrozole and anastrozole appear to increase senescence through the same YPEL3 direction.

That helps explain why different endocrine drugs may push cells into different survival states.

CDK4/6 inhibitors and reversible senescence

The authors give special attention to palbociclib.

In ER-positive cell lines such as MCF-7 and T-47D, palbociclib induced senescence.

That senescence was:

• Rb-dependent

• biologically real by standard markers

• reversible after drug withdrawal in some models

That reversibility is a major point.

It suggests that growth arrest alone may not be enough.

The surviving cells may still need a second strike.

The three drug approaches around senescence

McGrath et al. (2024) outline three broad strategies.

• Senostatics try to deepen or prolong growth arrest.

• Senomorphics try to calm SASP.

• Senolytics try to kill the senescent cells themselves.

The most important senolytic example in the review is navitoclax (ABT-263).

Its logic is clear.

Senescent cells often protect themselves with high Bcl-2 family signalling.

Navitoclax tries to strip away that protection.

The paper also highlights early ARV-825 data in a palbociclib-plus-fulvestrant context.

Where autophagy and senescence meet

These pathways are not sealed off from each other.

The authors treat them as connected.

When autophagy was blocked during palbociclib treatment, cells were often pushed into a deeper, more irreversible senescence.

That suggests autophagy can protect cells from fully committing to that arrested state.

This is one reason the sequencing question matters so much.

What still needs answering

McGrath et al. (2024) leave several questions open:

• when to add a senolytic

• whether it should come during treatment or after a defined arrest period

• how to identify truly senescent disseminated tumour cells in patients

• which biomarker best captures the dangerous, relapse-relevant phenotype

Bottom line

Senescence can slow cancer.

It can also shelter cancer.

McGrath et al. (2024) focus on that second possibility.

The key concern is not simple growth arrest.

It is survival, inflammatory signalling, and later re-entry.